Clinical data | |
---|---|
Other names | 07-PNET, fosnetupitant chloride hydrochloride |
ATC code |
|
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C31H35F6N4O5P |
Molar mass | 688.608 g·mol−1 |
Fosnetupitant is a medication used for the treatment of chemotherapy-induced nausea and vomiting. It is a prodrug of netupitant. [1] It is used in combination with palonosetron hydrochloride and formulated as the salt fosnetupitant chloride hydrochloride for intravenous use. [2]
In 2018, the US Food and Drug Administration approved the intravenous formulation of a fixed dose combination of fosnetupitant and palonosetron. [3] [4] The combination is also approved for medical use in the European Union [5] and in Canada. [6]